Ganli Pharmaceutical: The Phase III clinical trial of Bovine Gallbladder Polypeptide Injection has completed the first dose in the new indication.

Ganli Pharmaceutical announced that its wholly-owned subsidiary, Ganli Pharmaceutical Shandong Co., Ltd., independently developed Bofanggru peptide injection has successfully completed the first dosing of the first subject in the phase III clinical trial in China for the indication of moderate to severe obstructive sleep apnea in adult obese patients.